This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Transplantation				
Graft-versus-host disease (GvHD)	CD4	A study in mice suggests that mAbs against CD4 could help treat bone marrow GvHD (BM-GvHD). In a mouse model of BM-GvHD, an anti-CD4 mAb increased survival and reduced symptom severity compared with a control anti-CD8 mAb. Next steps include confirming the mouse results in humans. Anti-CD4 802-2, a CD4 receptor inhibitor targeting CD4 from Adeona Pharmaceuticals Inc., is in Phase I/II testing for GvHD. Five different companies have anti-CD4 antibodies in various phases of development to treat autoimmune and infectious disease. SciBX 3(15); doi:10.1038/scibx.2010.476 Published online April 15, 2010	Patent application filed covering use of anti-CD4 antibody therapy in bone marrow hematopoietic stem cell transplantation to avoid BM-GvHD; available for licensing	Shono, Y. <i>et al. Blood</i>; published online March 30, 2010; doi:10.1182/blood-2009-11-253559 Contact: Kouji Matsushima, The University of Tokyo, Tokyo, Japan e-mail: koujim@m.u-tokyo.ac.jp